Abstract
The pharmacophore modeling in modern drug research has been applied for both bioactivity profiling and early stage of risk assessment of potential side effects and toxicity due to interactions of drug candidates with antitargets namely P-glycoprotein, hERG, cytochrome P450 and pregnane X-receptor. In this article, an existing state concerning with pharmacophore modeling applied for promiscuous proteins in drug research were updated and reviewed. In an attempt to create new safe medicines faster, the partial overlap of substrate properties of hERG, P-glycoprotein, pregnane X-receptor and cytochrome P450 has to be considered and drug safety has to be dealt on a system level on the off-targets.
Publication types
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / antagonists & inhibitors*
-
ATP Binding Cassette Transporter, Subfamily B, Member 1 / metabolism
-
Animals
-
Cytochrome P-450 Enzyme Inhibitors*
-
Cytochrome P-450 Enzyme System / metabolism
-
Drug Discovery*
-
Ether-A-Go-Go Potassium Channels / antagonists & inhibitors*
-
Ether-A-Go-Go Potassium Channels / metabolism
-
Humans
-
Models, Molecular
-
Pregnane X Receptor
-
Receptors, Steroid / antagonists & inhibitors*
-
Receptors, Steroid / metabolism
Substances
-
ATP Binding Cassette Transporter, Subfamily B, Member 1
-
Cytochrome P-450 Enzyme Inhibitors
-
Ether-A-Go-Go Potassium Channels
-
Pregnane X Receptor
-
Receptors, Steroid
-
Cytochrome P-450 Enzyme System